Hepatokine levels during the first or early second trimester of pregnancy and the subsequent risk of gestational diabetes mellitus: a systematic review and meta-analysis.

Published in: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals (2021)

Measurement of circulating hepatokines in the first or second trimester of pregnancy may improve the identification of women at risk of developing GDM later. Prospective evaluation of the combination of hepatokines and maternal characteristics for early identification of those who do and do not require OGTT is warranted. Additional well-designed prospective studies with longitudinal assessment of hepatokines during pregnancy are needed to understand the trajectories and dynamic associations of hepatokines with GDM risk.

Keyphrases

pregnancy outcomes
pregnant women
preterm birth
bioinformatics analysis
type diabetes
cross sectional
metabolic syndrome
body mass index
adipose tissue
polycystic ovary syndrome
case control
skeletal muscle
physical activity